In this issue:
4-year outcomes for first-line nivolumab + ipilimumab with chemotherapy for metastatic NSCLC
OS and CNS activity of crizotinib in ROS1-rearranged lung cancer
Treatments and OS improvements since 2011 for advanced/metastatic NSCLC
Olaparib ± ceralasertib in SCLC
ABCP for EGFR-mutated NSCLC after TKI failure
Sitravatinib + nivolumab versus docetaxel in advanced nonsquamous NSCLC
Amivantamab + chemotherapy ± lazertinib in EGFR-mutated advanced NSCLC after progression on osimertinib
First-line avelumab vs. platinum doublet for PD-L1-positive metastatic NSCLC
Updated efficacy and safety of entrectinib in NTRK fusion-positive NSCLC
High-dose third-generation EGFR-TKIs for EGFR-mutated NSCLC with leptomeningeal metastasis
Please login below to download this issue (PDF)